Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Glioma

• Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients
• Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
• Study of Olutasidenib and Temozolomide in HGG
• Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)
• Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
• A Study of Avutometinib for People With Solid Tumor Cancers
• Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) Participants With EGFR Alterations or Fusions
• A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma
• Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
• Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
• Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
• A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
• Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Recurrent or Progressed Following Treatment
• Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma
• Study of Ribociclib and Everolimus in HGG and DIPG
• B7-H3-CAR T Cells for Pediatric CNS Tumors
• Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults
• Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients With Glioblastoma
• Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
• Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
• FUS Etoposide for DMG - A Feasibility Study
• Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)
• Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
• A Study of Temodar With PCI-24781 for Patients With Recurrent Glioma
• Venous Thromboembolism Prevention in Outpatients With Glioma
• Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma, a Pilot Study
• CARv3-TEAM-E T Cells in Glioblastoma
• Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)
• Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma
• Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence
• Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
• ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
• Study of Zotiraciclib for Recurrent High-Grade Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
• ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
• A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma
• 68Ga-P16-093 PET/CT Imaging in Glioma Patients
• DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy
• Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma
• Neoantigens Phase I Trial in Newly Diagnosed Glioblastoma Patients
• Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
• 18F-Fluciclovine PET-MRI in High-grade Glioma
• A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I)
• Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma
• Evaluation of Diagnostic Performances of 18F-FDOPA PET KInetics
• 18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy
• Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma
• Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
• Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
• Efficacy and Safety Evaluation of Percutaneous Ommaya Capsule Injection of Autologous Bi-dimensional Specific T Cells in the Treatment of Glioma and in Combination With Pemetrexed in the Treatment of Brain/Meningeal Metastases
• Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant
• Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
• Niraparib In Recurrent LDH 1/2 Gliomas
• AsiDNA Children, Adolescents and Young Adults
• Registering Genomics and Imaging of Tumors (ReGIT)
• ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab
• Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma
• Effects of Propofol on Auditory Event-related Potentials and Brain Functional Connectivity in Patients With Supratentorial Glioma
• A Phase 2 Trial of All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
• AB-218 Safety and Efficacy Study in Patients With IDH1 Mutant Glioma
• PARP Inhibition for Gliomas (PI-4G or π4g)
• ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM
• Modified CV Regimen in Optic Pathway Glioma
• Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors or Meningiomas Expressing SST2A
• Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
• Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
• Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
• Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
• Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
• Phase 0 Plus Expansion Study of AZD1390 in Recurrent GBM Patients
• Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy
• A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma and H3 K27M-Mutant High-Grade Glioma
• PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
• A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas
• Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
• Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma
• Preoperative Radiosurgery for the Treatment of High Grade Glioma, The NeoGlioma Study
• Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
• Combination Therapy for the Treatment of Diffuse Midline Gliomas
• Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide
• rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
• The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation
• SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
• Bispecific T Cell Engager BRiTE for Patients With Grade IV Malignant Glioma
• A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
• CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
• NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
• ASP8374 + Cemiplimab in Recurrent Glioma
• A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma
• Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
• A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas
• Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)
• A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
• Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
• A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma
• Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas
• A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)
• Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd
• ONC206 for Treatment of Newly Diagnosed, or Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant Brain Tumors (PNOC 023)
• Anlotinib to Malignant Brainstem Glioma
• Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas
• A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
• Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy
• Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
• Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
• A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma
• Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
• HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM
• A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
• Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
• Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
• Nimotuzumab in Combined With Concurrent Radiochemotherapy in the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Children
• Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
• Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
• Effect of Perampanel on Peritumoral Hyperexcitability in HGG
• Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients With Recurrent Low Grade Gliomas (PNOC021)
• HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
• A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma
• Infigratinib in Recurrent High-Grade Glioma Patients
• Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
• Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.
• Phase I Study of Marizomib + Panobinostat for Children With DIPG
• A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
• Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
• Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery
• Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma
• Study of 2-hydroxyoleic Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
• INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
• Study of Recombinant Human Endostatin Combined With Temozolomide and Irinotecan in Recurrent Gliomas
• Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma
• CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas
• Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade Gliomas
• Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma
• A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
• Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas
• GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)
• Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
• Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.
• A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
• Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
• D2C7-IT With Atezolizumab for Recurrent Gliomas
• Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma
• C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
• Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma
• A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
• A Phase II Study of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
• Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
• Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma
• Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
• Fluoroethyltyrosine in Detecting Tumors in Participants With Recurrent Intracranial Tumors
• The Effects of Mild Sedation on Motor Function Networks in Patients With Brian Gliomas
• Pediatric Long-Term Follow-up and Rollover Study
• Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
• Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma
• Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
• Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ
• First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression
• Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma
• Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas
• Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
• BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
• Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma Patients
• AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma
• Fimepinostat in Treating Brain Tumors in Children and Young Adults
• Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG
• A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
• Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma
• A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection
• Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation
• Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
• Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse
• 18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy
• Trial in Low Grade Glioma Patients: Wait or Treat
• Azoles Targeting Recurrent High Grade Gliomas
• BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
• Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
• TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT
• Hyperpolarized Imaging in Diagnosing Participants With Glioma
• A Study Utilizing Escitalopram in Glioma Patients
• Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma
• Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
• Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
• Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases
• Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas
• REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
• rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide
• A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
• 9-ING-41 in Patients With Advanced Cancers
• A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
• Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
• A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
• A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
• Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
• Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
• GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas
• MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
• Olaparib in Recurrent IDH-mutant Glioma
• Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
• INCMGA00012 and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
• Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
• Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
• Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
• Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)
• ABI-009 (Nab-rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
• Seizure Prophylaxis Study
• SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
• DAY101 In Gliomas and Other Tumors
• ONC201 in Pediatric H3 K27M Gliomas
• IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Lower Grade Glioma
• Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)
• A Study of Apatinib in Recurrent or Recurrent High-grade Glioma
• Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
• Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
• A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
• Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations
• Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
• Dabrafenib and/or Trametinib Rollover Study
• Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas
• A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
• Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours
• PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
• Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma
• ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
• Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
• Quality of Life and Neurocognitive Functioning
• International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)
• The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
• A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
• Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
• Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
• Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
• Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
• Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
• Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy
• Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
• Image-Based Quantitative Assessment of Acute Radiation-Induced Changes in Glioma
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
• Chronic Convection Enhanced Delivery of Topotecan
• A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
• VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
• HUMC 1612: Optune NovoTTF-200A System
• CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)
• Treatment of High-grade Gliomas Using Hypofractionated Radiation Therapy -a Phase I Clinical Trial
• Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
• Seizure Treatment in Glioma
• Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas
• Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma
• Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
• Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
• Phase 2 Study of IDH305 in Low Grade Gliomas
• PVSRIPO With/Without Lomustine
• Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas
• Trial of IDH305 in IDH1 Mutant Grade II or III Glioma
• Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas
• Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas
• Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
• H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
• Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
• A Microdose Evaluation Study of ABY-029 in Recurrent Glioma
• Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
• Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma
• Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
• Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma
• Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma
• Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
• Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
• Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma
• Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
• Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
• Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion"
• Temozolomide Chronotherapy for High Grade Glioma
• Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
• CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas
• First in Patient Study for PF-06840003 in Malignant Gliomas
• Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma
• A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
• Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
• A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)
• Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
• Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
• Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
• TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
• Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
• Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
• Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
• Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors
• Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
• 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
• A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas
• A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy
• A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care
• Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
• Terameprocol in Treating Patients With Recurrent High Grade Glioma
• Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma
• Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
• Nivolumab With DC Vaccines for Recurrent Brain Tumors
• Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma
• 68Ga-NOTA-Aca-BBN(7-14) PET/CT in Patients With Primary Gliomas
• Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
• Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas
• Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
• Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection
• Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas
• Metformin And Chloroquine in IDH1/2-mutated Solid Tumors
• Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas
• Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
• Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
• A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma
• Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas
• gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas
• Sedatives' Effects on Neurological Function in Patients With Eloquent Area Glioma
• Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
• Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas
• Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
• Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
• FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas
• Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
• Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia
• Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma
• Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
• Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
• A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation
• Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
• Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
• Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
• Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
• Study of Tumor Metabolism by Isotopic Tagging in Patients With High-grade Glioma (CARBONOMIC)
• D2C7 for Adult Patients With Recurrent Malignant Glioma
• Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma
• Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors
• Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases
• Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma
• Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
• Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide (D-TERMINED)
• Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas
• HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)
• Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
• Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery
• Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
• A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas
• Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
• Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
• Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
• Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
• 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
• 5-ALA in Recurrent Glioma
• Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas
• A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas
• Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
• Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
• Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
• Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
• A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
• Everolimus With and Without Temozolomide in Adult Low Grade Glioma
• Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma
• 18F-DOPA-PET in Planning Surgery in Patients With Gliomas
• Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors
• 18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy
• Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma
• Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
• Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
• ANG1005 in Patients With Recurrent High-Grade Glioma
• Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
• C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression
• Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
• Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients
• Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
• Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
• STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
• A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma
• Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults
• Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults
• Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
• FMISO-PET in Brain Tumors and SCS Effect
• Valproic Acid in Childhood Progressive Brain Tumors
• A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
• Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients
• Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma
• Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
• 68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma
• A Phase 1/2A Study of Minerval in Adult Patients With Advanced Solid Tumours
• Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma
• Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
• A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas
• Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas
• A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
• Phase I/II Cabazitaxel for Recurrent Malignant Glioma
• Bevacizumab Beyond Progression (BBP)
• Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
• PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
• Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide
• Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).
• A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
• Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas
• Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
• Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas
• Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors
• Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma
• Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma
• Carboplatin in Treating Patients With Recurrent High-Grade Gliomas
• Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
• Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma
• Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma
• Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas
• Study of DC Vaccination Against Glioblastoma
• Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
• Pilot Immunotherapy Trial for Recurrent Malignant Gliomas
• A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
• Efficacy Study of Radiotherapy Alone Versus CCRT With Temozolomide in Grade III Gliomas Without 1p/19q Codeletion
• Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents
• Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
• Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy
• Fluorescence-guided Surgery for Low- and High-grade Gliomas
• Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas
• Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma
• Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
• AMG 595 First-in-Human in Recurrent Gliomas
• Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma
• Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
• Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT
• CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
• Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
• More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
• A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
• Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
• Lacosamide in Preventing Seizures in Participants With Malignant Glioma
• Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
• A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain
• Nuvigil or Placebo in Newly Diagnosed Malignant Glioma
• Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma
• PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma
• A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma
• An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
• High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma
• A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors
• Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
• Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas
• Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
• Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas
• AZD8055 for Adults With Recurrent Gliomas
• Low Dose Naltrexone for Glioma Patients
• RO4929097 in Treating Patients With Recurrent Invasive Gliomas
• Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
• Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma
• EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
• Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
• MK-2206 for Recurrent Malignant Glioma
• Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
• Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
• Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas
• Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
• A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
• Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
• RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
• A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
• Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
• A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
• Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas
• Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma
• Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma
• Bevacizumab in Recurrent Grade II and III Glioma
• Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas
• A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma
• Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors
• Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma
• Cellular Immunotherapy Study for Brain Cancer
• Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
• A Study in Subjects With Recurrent Malignant Glioma
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
• RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
• A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas
• Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain
• AMG 102 and Avastin for Recurrent Malignant Glioma
• Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastom
• Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
• Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
• Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
• Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
• Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
• Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
• Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
• Hypertension Monitoring in Glioma Patients Treated With Bevacizumab
• A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma
• Panitumumab and Irinotecan for Malignant Gliomas
• Radiosurgery and Avastin for Recurrent Malignant Gliomas
• Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
• Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)
• A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
• Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
• Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide
• Image-Guided Stereotactic Biopsy of High Grade Gliomas
• Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma
• Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
• Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)
• ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
• Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
• Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
• Sunitinib to Treat Recurrent Brain Cancer
• Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme
• Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1)
• Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide
• A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
• Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
• Sorafenib in Newly Diagnosed High Grade Glioma
• An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma
• Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
• ADV-TK Improves Outcome of Recurrent High-Grade Glioma
• LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
• Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors
• Everolimus in Treating Patients With Recurrent Low-Grade Glioma
• Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma
• Everolimus in Treating Patients With Recurrent Low-Grade Glioma
• Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas
• DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas
• Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
• Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas
• A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
• Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
• A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
• Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
• BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma
• Study of Capecitabine to Treat Recurrent High Grade Gliomas
• Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)
• A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas
• Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma
• A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma
• Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
• Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
• Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
• Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
• Study of Aminolevulinic Acid to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain
• O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
• A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma
• A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma
• Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
• Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
• Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab
• A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
• Temozolomide in Treating Patients With Recurrent High-Grade Glioma
• Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide
• Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas
• Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma
• Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma
• PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
• Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas
• Ph I SU011248 + Irinotecan in Treatment of Pts w MG
• Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma
• Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
• Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
• Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma
• Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas
• Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02)
• A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas
• Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas
• Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)
• Nimotuzumab in Children With Intrinsic Pontine Glioma
• Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
• Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM
• The Safety and Efficacy of DCA for the Treatment of Brain Cancer
• A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
• A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas
• A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas
• Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas
• VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma
• Temozolomide and Radiation Therapy in Treating Young Patients With Pontine Glioma
• Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
• 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
• Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma
• Sunitinib in Treating Patients With Recurrent Malignant Gliomas
• Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
• Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas
• Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
• A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma
• Vandetanib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Diffuse Brainstem Glioma
• Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy
• Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy
• Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas
• Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
• Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma
• A Phase II Study to Treat Advanced Malignant Glioma
• Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)
• Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma
• Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
• Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma
• Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
• Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma
• Bevacizumab and Irinotecan to Treat Brain Tumors
• The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
• A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
• Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma
• Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
• 131-I-TM-601 Study in Adults With Solid Tumors
• Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma
• Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
• Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma
• Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
• Capecitabine and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Nonmetastatic Brain Stem Glioma or High-Grade Glioma
• Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
• Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma
• Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
• ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma
• Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma
• A Phase I Study of ECO-4601 in Patients With Advanced Cancer
• A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)
• AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
• A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas
• Temozolomide in Treating Patients With Low-Grade Glioma
• Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
• Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
• High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma
• Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma
• Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
• Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases
• Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas
• Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
• O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors
• ZD6474 to Treat Advanced Brain Cancer in Patients
• Bevacizumab for Recurrent Malignant Glioma
• Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
• Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
• Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma
• Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma
• A Study of LY317615 in Patients With Brain Tumors
• Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma
• Radiation Therapy or Temozolomide in Treating Patients With Gliomas
• Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma
• Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
• Prolonged Daily Temozolomide for Low-Grade Glioma
• G207 Followed by Radiation Therapy in Malignant Glioma
• Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents
• Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
• High Light and Low Light Dose PDT in Glioma
• 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
• Temozolomide and Radiation Therapy in Treating Patients With Gliomas
• Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
• Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
• Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
• Enzastaurin to Treat Recurrent Brain Tumor
• Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma
• GW572016 to Treat Recurrent Malignant Brain Tumors
• Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
• Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
• Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
• Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
• Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas
• Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
• IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
• Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)
• Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma
• Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
• A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas
• Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma
• Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
• Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma
• Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas
• Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors
• Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas
• CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas
• Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
• Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
• Talampanel in Treating Patients With Recurrent High-Grade Glioma
• Cilengitide in Treating Children With Refractory Primary Brain Tumors
• Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
• FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
• Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
• Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
• Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
• Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
• Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
• Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma
• Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
• Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
• Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
• Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
• Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.
• Imatinib Mesylate in Treating Patients With Gliomas
• Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas
• Study of Vioxx and Radiation Therapy for Brainstem Glioma
• CC-5013 in Treating Patients With Recurrent Glioma
• SarCNU in Treating Patients With Recurrent Malignant Glioma
• This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.
• Paclitaxel Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
• Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma
• Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer
• Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
• Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
• Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
• Radiation Therapy and Tamoxifen in Treating Children With Newly Diagnosed Brain Stem Glioma
• CCI-779 in Treating Patients With Malignant Glioma
• Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma
• Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma
• Karenitecin in Treating Patients With Recurrent Malignant Glioma
• Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma
• Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
• Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
• Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm
• Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
• Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma
• Immunotoxin Therapy in Treating Patients With Malignant Glioma
• Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma
• Fenretinide in Treating Patients With Recurrent Malignant Glioma
• Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
• Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma
• Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
• Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma
• Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma
• Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma
• Radiation Therapy Plus Carboplatin and Lobradimil in Treating Children With Newly Diagnosed Brain Stem Gliomas
• Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma
• O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma
• SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
• Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
• Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma
• Temozolomide in Treating Patients With Recurrent Malignant Glioma
• Irinotecan in Treating Children With Refractory Solid Tumors
• Carmustine in Treating Patients With Recurrent Malignant Glioma
• Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
• Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
• Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma
• Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma
• Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma
• Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas
• Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma
• Antineoplaston Therapy in Treating Children With Visual Pathway Glioma
• Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
• Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma
• Temozolomide in Treating Patients With Progressive Low-Grade Glioma
• Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
• Antineoplaston Therapy in Treating Patients With Brain Stem Glioma
• Irinotecan in Treating Patients With Recurrent Malignant Glioma
• Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
• Irinotecan in Treating Patients With Recurrent Glioma
• Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma
• Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma
• Chemotherapy in Treating Patients With Recurrent Malignant Glioma
• O(6)-Benzylguanine in Treating Patients With Malignant Glioma
• Carboplatin in Patients With Progressive Gliomas
• A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy
• A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors